close
References
  1. Corchado-Cobos R, García-Sancha N, González-Sarmiento R, Pérez-Losada J, Cañueto J. Cutaneous squamous cell carcinoma: from biology to therapy. Int J Mol Sci. 2020;21(8):2956.
  2. Howell JY, Ramsey ML. Squamous Cell Skin Cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. www.ncbi.nlm.nih.gov/books/NBK441939. Accessed July 16, 2020.
  3. Robert C, Peris K, Migden M. Unlocking the potential of immuno-oncology in advanced cutaneous squamous cell carcinoma: role of checkpoint blockade. EMJ Dermatol. 2019;7(suppl 1):2-10.
  4. Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol. 2017;31(suppl 2):5-7.
  5. Riihilä P, Nissinen L, Knuutila J, Rahmati Nezhad P, Viiklepp K, Kähäri VM. Complement system in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20(14):3550.
  6. Bottomley MJ, Thomson J, Harwood C, Leigh I. The role of the immune system in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20(8):2009.
  7. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500-2501.
  8. Nissinen L, Farshchian M, Riihilä P, Kähäri VM. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma. Cell Tissue Res. 2016;365(3):691-702.
  9. Ogata D, Tsuchida T. Systemic immunotherapy for advanced cutaneous squamous cell carcinoma. Curr Treat Options Oncol. 2019;20(4):30.
  10. Fitzgerald K, Tsai KK. Systemic therapy for advanced cutaneous squamous cell carcinoma. Semin Cutan Med Surg. 2019;38(1):E67-E74.
  11. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78(2):237-247.
  12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer. Version 2.2020. July 14, 2020. www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed July 25, 2020.
  13. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976-990.
  14. Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012;106(7):811-815.
  15. Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg. 2006;32(11):1309-1321.
  16. Karia PS, Morgan FC, Ruiz ES, Schmults CD. Clinical and incidental perineural invasion of cutaneous squamous cell carcinoma: a systematic review and pooled analysis of outcomes data. JAMA Dermatol. 2017;153(8):781-788.
  17. Jennings L, Schmults CD. Management of high-risk cutaneous squamous cell carcinoma. J Clin Aesthet Dermatol. 2010;3(4):39-48.
  18. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol. 2016;152(4):419-428.
  19. American Joint Committee on Cancer. Physician to Physician AJCC 8th Edition 1, Head and Neck. 2018. https://cancerstaging.org/CSE/Physician/Documents/8E%20Head%20and%20Neck%20Lydiatt_handout.pdf. Accessed July 29, 2020.
  20. American Joint Committee on Cancer. AJCC Cancer Staging Manual, Eighth Edition, Staging Form Supplement. 2018. https://cancerstaging.org/references-tools/deskreferences/Documents/AJCC%20Cancer%20Staging%20Form%20Supplement.pdf. Accessed July 29, 2020.
  21. American Joint Committee on Cancer. AJCC Cancer Staging Manual, Seventh Edition. 2010. https://cancerstaging.org/references-tools/deskreferences/Documents/AJCC%207th%20Ed%20Cancer%20Staging%20Manual.pdf. Accessed August 1, 2020.
  22. Ruiz ES, Karia PS, Besaw R, Schmults CD. Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women's Hospital Tumor Classification System for cutaneous squamous cell carcinoma. JAMA Dermatol. 2019;155(7):819-825.
  23. Koyfman SA, Cooper JS, Beitler JJ, et al. ACR Appropriateness Criteria aggressive nonmelanomatous skin cancer of the head and neck. Head Neck. 2016;38(2):175-182.
  24. van Lee CB, Roorda BM, Wakkee M, et al. Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study. Br J Dermatol. 2019;181(2):338-343.
  25. Potenza C, Bernardini N, Balduzzi V, et al. A review of the literature of surgical and nonsurgical treatments of invasive squamous cells carcinoma. Biomed Res Int. 2018;2018:9489163.
  26. Work Group; Invited Reviewers, Kim JYS, Kozlow JH, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560-578.
  27. Likhacheva A, Awan M, Barker CA, et al. Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol. 2020;10(1):8-20.
  28. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249-261.
  29. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419-3426.
  30. Foote MC, McGrath M, Guminski A, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014;25(10):2047-2052.
  31. Samstein RM, Ho AL, Lee NY, Barker CA. Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy. J Skin Cancer. 2014;2014:284582.
  32. Porceddu SV, Bressel M, Poulsen MG, et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial. J Clin Oncol. 2018;36(13):1275-1283.
  33. Cemiplimab-rwlc. Package insert. Regeneron Pharmaceuticals, Inc.; 2020.
  34. Ahmed SR, Petersen E, Patel R, Migden MR. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol. 2019;12(10):947-951.
  35. Food and Drug Administration. FDA approves pembrolizumab for cutaneous squamous cell carcinoma. www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinoma. June 24, 2020. Accessed November 23, 2020.
  36. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015:76-83.
  37. Migden MR, Schlesinger TE, Schmults CD, et al. Multidisciplinary expert-driven consensus on the evolving treatment of patients with advanced cutaneous squamous cell carcinoma. SKIN The Journal of Cutaneous Medicine. 2019;3:S50.
  38. Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341-351.
  39. Grob JJ, Gonzalez R, Basset-Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J Clin Oncol. 2020;38(25):2916-2925.
  40. Maubec E, Boubaya M, Petrow P, et al; Groupe de Cancérologie Cutanée30. Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas. J Clin Oncol. 2020;38(26):3051-3061.
  41. Vaidya P, Mehta A, Ragab O, Lin S, In GK. Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2019;5(9):763-766.
  42. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=Cutaneous+Squamous+Cell+Carcinoma&flds=aby&recrs=b&recrs=a&age_v=&gndr=&type=Intr&rslt=&Search=Apply. Accessed July 12, 2020.
  43. Association of Community Cancer Centers. Multidisciplinary Advanced Cutaneous Squamous Cell Carcinoma Care: Models of Effective Care Delivery. 2019. www.accc-cancer.org/projects/advanced-squamous-cell-carcinoma/overview. Accessed November 24, 2020.